{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:44:31Z","timestamp":1791045871876,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute","award":["CA008748"],"award-info":[{"award-number":["CA008748"]}]},{"name":"National Cancer Institute","award":["CA201250"],"award-info":[{"award-number":["CA201250"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To introduce a biomarker-based dosimetry method for the rational selection of a treatment activity for patients undergoing radioactive iodine\n                      <jats:sup>131<\/jats:sup>\n                      I therapy (RAI) for metastatic differentiated thyroid cancer (mDTC) based on single-timepoint imaging of individual lesion uptake by\n                      <jats:sup>124<\/jats:sup>\n                      I PET.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients referred for RAI therapy of mDTC were enrolled in institutionally approved protocols. A total of 208 mDTC lesions (in 21 patients) with SUV\n                      <jats:sub>max<\/jats:sub>\n                      \u2009&gt;\u20091 underwent quantitative PET scans at 24, 48, 72, and 120\u00a0h post-administration of 222\u00a0MBq of theranostic NaI-\n                      <jats:sup>124<\/jats:sup>\n                      I to determine the individual lesion radiation-absorbed dose. Using a general estimating equation, a prediction curve for biomarker development was generated in the form of a best-fit regression line and 95% prediction interval, correlating individual predicted lesion radiation dose metrics, with candidate biomarkers (\u201cpredictors\u201d) such as SUV\n                      <jats:sub>max<\/jats:sub>\n                      and activity in microcurie per gram, from a single imaging timepoint.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the 169 lesions (in 15 patients) that received\n                      <jats:sup>131<\/jats:sup>\n                      I therapy, individual lesion cGy varied over 3 logs with a median of 22,000\u00a0cGy, confirming wide heterogeneity of lesion radiation dose. Initial findings from the prediction curve on all 208 lesions confirmed that a 48-h SUV\n                      <jats:sub>max<\/jats:sub>\n                      was the best predictor of lesion radiation dose and permitted calculation of the\n                      <jats:sup>131<\/jats:sup>\n                      I activity required to achieve a lesional threshold radiation dose (2000\u00a0cGy) within defined confidence intervals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Based on MIRD lesion-absorbed dose estimates and regression statistics, we report on the feasibility of a new single-timepoint\n                      <jats:sup>124<\/jats:sup>\n                      I-PET-based dosimetry biomarker for RAI in patients with mDTC. The approach provides clinicians with a tool to select personalized (precision) therapeutic administration of radioactivity (MBq) to achieve a desired target lesion-absorbed dose (cGy) for selected index lesions based on a single 48-h measurement\n                      <jats:sup>124<\/jats:sup>\n                      I-PET image, provided the selected activity does not exceed the maximum tolerated activity (MTA) of\u2009&lt;\u20092\u00a0Gy to blood, as is standard of care at Memorial Sloan Kettering Cancer Center.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT04462471, Registered July 8, 2020.<\/jats:p>\n                    <jats:p>NCT03647358, Registered Aug 27, 2018.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-023-06240-1","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T01:01:56Z","timestamp":1683853316000},"page":"2971-2983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients"],"prefix":"10.1007","volume":"50","author":[{"given":"Audrey","family":"Mauguen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder K.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Augensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Abusamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vetri Sudar","family":"Jayaprakasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette Z. Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Ghossein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u04e7der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Michael","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Humm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-7507","authenticated-orcid":false,"given":"Steven M.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"6240_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1089\/thy.2011.0535","volume":"22","author":"IJ Nixon","year":"2012","unstructured":"Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012;22:884\u20139.","journal-title":"Thyroid"},{"key":"6240_CR2","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"6240_CR3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.107.047159","volume":"49","author":"W Jentzen","year":"2008","unstructured":"Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49:1017\u201323.","journal-title":"J Nucl Med"},{"key":"6240_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1089\/thy.2015.0482","volume":"26","author":"SA Gulec","year":"2016","unstructured":"Gulec SA, Kuker RA, Goryawala M, et al. (124)I PET\/CT in patients with differentiated thyroid cancer: clinical and quantitative image analysis. Thyroid. 2016;26:441\u20138.","journal-title":"Thyroid"},{"key":"6240_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2967\/jnumed.115.168799","volume":"57","author":"R Wierts","year":"2016","unstructured":"Wierts R, Brans B, Havekes B, et al. Dose-response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET\/CT. J Nucl Med. 2016;57:1027\u201332.","journal-title":"J Nucl Med"},{"key":"6240_CR6","first-page":"1557","volume":"37","author":"KS Pentlow","year":"1996","unstructured":"Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37:1557\u201362.","journal-title":"J Nucl Med"},{"key":"6240_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2967\/jnumed.115.168138","volume":"57","author":"JW Kist","year":"2016","unstructured":"Kist JW, de Keizer B, van der Vlies M, et al. 124I PET\/CT to predict the outcome of blind 131i treatment in patients with biochemical recurrence of differentiated thyroid cancer: results of a multicenter diagnostic cohort study (THYROPET). J Nucl Med. 2016;57:701\u20137.","journal-title":"J Nucl Med"},{"key":"6240_CR8","doi-asserted-by":"publisher","first-page":"34s","DOI":"10.2967\/jnumed.116.186866","volume":"58","author":"J Nagarajah","year":"2017","unstructured":"Nagarajah J, Janssen M, Hetkamp P, Jentzen W. Iodine symporter targeting with (124)I\/(131)I theranostics. J Nucl Med. 2017;58:34s\u20138s.","journal-title":"J Nucl Med"},{"key":"6240_CR9","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.2967\/jnumed.115.170571","volume":"57","author":"W Jentzen","year":"2016","unstructured":"Jentzen W, Verschure F, van Zon A, et al. 124I PET Assessment of response of bone metastases to initial radioiodine treatment of differentiated thyroid cancer. J Nucl Med. 2016;57:1499\u2013504.","journal-title":"J Nucl Med"},{"key":"6240_CR10","unstructured":"Bartlett RM, Bolch WE, Bertrand Brill A, Dewaraja YK, Fahey FH, Fisher DR, Hobbs RF, Howell RW, Meredith RF, Rajendran JG, Sgouros G, Zanzonico P. MIRD primer 2022: a complete guide to radiopharmaceutical dosimetry. Society of Nuclear Medicine, Incorporated.\u00a0Release Date: November 2022 | 298 pages. ISBN: 978-0-932004-03-1"},{"key":"6240_CR11","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1038\/sj.onc.1206602","volume":"22","author":"JA Knauf","year":"2003","unstructured":"Knauf JA, Kuroda H, Basu S, Fagin JA. RET\/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene. 2003;22:4406\u201312.","journal-title":"Oncogene"},{"key":"6240_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368:623\u201332.","journal-title":"N Engl J Med"},{"key":"6240_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022;33:27\u201363.","journal-title":"Endocr Pathol"},{"key":"6240_CR14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2967\/jnumed.106.035774","volume":"48","author":"M Soret","year":"2007","unstructured":"Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932\u201345.","journal-title":"J Nucl Med"},{"key":"6240_CR15","doi-asserted-by":"crossref","unstructured":"Gelman A, Hill J (2007) Data analysis using regression and hierarchical\/multilevel models. New York, NY, Cambridge","DOI":"10.1017\/CBO9780511790942"},{"key":"6240_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.clon.2017.01.002","volume":"29","author":"F Sun","year":"2017","unstructured":"Sun F, Gerrard GE, Roberts JK, et al. Ten year experience of radioiodine dosimetry: is it useful in the management of metastatic differentiated thyroid cancer? Clin Oncol (R Coll Radiol). 2017;29:310\u20135.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"6240_CR17","first-page":"171","volume":"87","author":"RS Benua","year":"1962","unstructured":"Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171\u201382.","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"6240_CR18","first-page":"131","volume":"40","author":"EE Furhang","year":"1999","unstructured":"Furhang EE, Larson SM, Buranapong P, Humm JL. Thyroid cancer dosimetry using clearance fitting. J Nucl Med. 1999;40:131\u20136.","journal-title":"J Nucl Med"},{"key":"6240_CR19","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJM198310203091601","volume":"309","author":"HR Maxon","year":"1983","unstructured":"Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937\u201341.","journal-title":"N Engl J Med"},{"key":"6240_CR20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2967\/jnumed.114.144089","volume":"55","author":"W Jentzen","year":"2014","unstructured":"Jentzen W, Hoppenbrouwers J, van Leeuwen P, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med. 2014;55:1759\u201365.","journal-title":"J Nucl Med"},{"key":"6240_CR21","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/mp.12886","volume":"45","author":"MT Madsen","year":"2018","unstructured":"Madsen MT, Menda Y, O\u2019Dorisio TM, O\u2019Dorisio MS. Technical note: single time point dose estimate for exponential clearance. Med Phys. 2018;45:2318\u201324.","journal-title":"Med Phys"},{"key":"6240_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40658-018-0224-9","volume":"5","author":"M Del Prete","year":"2018","unstructured":"Del Prete M, Arsenault F, Saighi N, et al. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized (177)Lu-octreotate PRRT. EJNMMI Phys. 2018;5:25.","journal-title":"EJNMMI Phys"},{"key":"6240_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40658-018-0232-9","volume":"5","author":"KP Willowson","year":"2018","unstructured":"Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following (177)Lu-DOTATATE ('Lutate\u2019) therapy. EJNMMI Phys. 2018;5:33.","journal-title":"EJNMMI Phys"},{"key":"6240_CR24","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1002\/mp.13446","volume":"46","author":"Y Seo","year":"2019","unstructured":"Seo Y, Huh Y, Huang SY, et al. Technical note: simplified and practical pretherapy tumor dosimetry - a feasibility study for (131) i-mibg therapy of neuroblastoma using (124) i-mibg pet\/ct. Med Phys. 2019;46:2477\u201386.","journal-title":"Med Phys."},{"key":"6240_CR25","doi-asserted-by":"publisher","first-page":"175006","DOI":"10.1088\/1361-6560\/ab3039","volume":"64","author":"W Zhao","year":"2019","unstructured":"Zhao W, Esquinas PL, Frezza A, Hou X, Beauregard JM, Celler A. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a (177)Lu-DOTATATE patient study. Phys Med Biol. 2019;64:175006.","journal-title":"Phys Med Biol"},{"key":"6240_CR26","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","volume":"61","author":"PA Jackson","year":"2020","unstructured":"Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation dosimetry in (177)Lu-PSMA-617 therapy using a single posttreatment spect\/ct scan: a novel methodology to generate time- and tissue-specific dose factors. J Nucl Med. 2020;61:1030\u20136.","journal-title":"J Nucl Med"},{"key":"6240_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40658-020-0273-8","volume":"7","author":"A Chicheportiche","year":"2020","unstructured":"Chicheportiche A, Ben-Haim S, Grozinsky-Glasberg S, et al. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. EJNMMI Phys. 2020;7:5.","journal-title":"EJNMMI Phys"},{"key":"6240_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40658-020-00293-z","volume":"7","author":"N Freedman","year":"2020","unstructured":"Freedman N, Sandstr\u00f6m M, Kuten J, et al. Personalized radiation dosimetry for PRRT-how many scans are really required? EJNMMI Phys. 2020;7:26.","journal-title":"EJNMMI Phys"},{"key":"6240_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.120.254656","volume":"62","author":"X Hou","year":"2021","unstructured":"Hou X, Brosch J, Uribe C, et al. Feasibility of single-time-point dosimetry for radiopharmaceutical therapies. J Nucl Med. 2021;62:1006\u201311.","journal-title":"J Nucl Med"},{"key":"6240_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40658-020-00339-2","volume":"7","author":"M Sandstr\u00f6m","year":"2020","unstructured":"Sandstr\u00f6m M, Freedman N, Fr\u00f6ss-Baron K, Kahn T, Sundin A. Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points. EJNMMI Phys. 2020;7:73.","journal-title":"EJNMMI Phys"},{"key":"6240_CR31","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.2967\/jnumed.120.256255","volume":"62","author":"TP Devasia","year":"2021","unstructured":"Devasia TP, Dewaraja YK, Frey KA, Wong KK, Schipper MJ. A novel time-activity information-sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT\/CT after (177)Lu-DOTATATE. J Nucl Med. 2021;62:1118\u201325.","journal-title":"J Nucl Med"},{"key":"6240_CR32","first-page":"803","volume":"63","author":"YH Kao","year":"2022","unstructured":"Kao YH. Single-time-point tumor dosimetry assuming normal distribution of tumor kinetics. J Nucl Med. 2022;63:803.","journal-title":"J Nucl Med"},{"key":"6240_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H H\u00e4nscheid","year":"2018","unstructured":"H\u00e4nscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with (177)Lu-DOTATATE\/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59:75\u201381.","journal-title":"J Nucl Med"},{"key":"6240_CR34","doi-asserted-by":"crossref","unstructured":"Gustafsson J, Taprogge J. Theoretical aspects on the use of single-time-point dosimetry for radionuclide therapy. Phys Med Biol. 2022;67:025003.","DOI":"10.1088\/1361-6560\/ac46e0"},{"key":"6240_CR35","first-page":"804","volume":"63","author":"G Sgouros","year":"2022","unstructured":"Sgouros G, Dewaraja YK, Escorcia F, et al. Reply: Single-time-point tumor dosimetry assuming normal distribution of tumor kinetics. J Nucl Med. 2022;63:804.","journal-title":"J Nucl Med"},{"key":"6240_CR36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1088\/1361-6560\/62\/3\/909","volume":"62","author":"R Barquero","year":"2017","unstructured":"Barquero R, Garcia HP, Incio MG, et al. (131)I activity quantification of gamma camera planar images. Phys Med Biol. 2017;62:909\u201326.","journal-title":"Phys Med Biol"},{"key":"6240_CR37","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.1118\/1.3635220","volume":"38","author":"V Bettinardi","year":"2011","unstructured":"Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PET\u2215CT Discovery-690. Med Phys. 2011;38:5394\u2013411.","journal-title":"Med Phys"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06240-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T22:05:46Z","timestamp":1690581946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06240-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6240"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06240-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2156223\/v1","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"14 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All studies were performed under IND #71343, with the prior approval of the MSK Radiation Safety Committee. Compliance issues were fully approved by the Committee on Compliance at MSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Steven M. Larson, Audrey Mauguen, Alan Ho, Ravinder Grewal, and John Humm are co-inventors of provisional patent for Soothsayer: Number 63\/193,700 filed on 5\/27\/21; conversion deadline: 5\/27\/22 \u201cSoothsayer,\u201d filed by Office of Technology Development, MSK. SM Larson reports receiving commercial research grants from Y-mAbs Therapeutics, Inc.; Genentech, Inc.; WILEX AG; Telix Pharmaceuticals Limited; and Regeneron Pharmaceuticals, Inc.; holding ownership interest\/equity in Elucida Oncology, Inc., and holding stock in ImaginAb, Inc., and Y-mAbs Therapeutics. SML is the inventor of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc.; Elucida Oncology, Inc.; and Y-mAbs Therapeutics, Inc. SML serves or has served as a consultant both compensated and uncompensated to Cynvec, LLC; Eli Lilly & Co.; Prescient Therapeutics Limited; Advanced Innovative Partners, LLC; Gerson Lehrman Group; Progenics Pharmaceuticals, Inc.; Exini, Inc.; and Janssen Pharmaceuticals, Inc. See\n                      \n                      \u2009=\u2009for further details.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}